19th Sep 2017 14:49
19 September 2017
Issue of Equity
Clinigen Group plc ("Clinigen" or the "Group", AIM: CLIN) announces that it has made an application for the admission to trading on AIM of 4,421 ordinary shares of 0.1 pence each in the Group (the "New Ordinary Shares"), which have been issued to satisfy the exercise of share options and rank pari passu with the existing shares of the Group. Admission to trading on AIM of the New Ordinary Shares is anticipated to occur at 8.00am on 20 September 2017.
At admission the issued share capital of the Group will consist of 115,165,344 ordinary shares, with no shares held in treasury. The total number of voting rights in the Group will therefore be 115,165,344.
Clinigen also announces today that it has applied for the admission of 44,742 ordinary shares of 0.1 pence each in the Group ("Shares") to trading on AIM.
These Shares were issued on the dates set out below pursuant to the exercise of share options by employees, but were not concurrently admitted to trading on AIM:
14,039 Shares on 21 October 2016
6,727 Shares on 2 November 2016
16,592 Shares on 5 January 2017
2,054 Shares on 13 January 2017
5,330 Shares on 17 May 2017
Admission of the Shares is expected to occur at 8.00am on 22 September 2017. There will be no change to the total issued share capital of the Company following admission of the Shares, which on admission of the New Ordinary Shares, will comprise 115,165,344 ordinary shares, with no shares held in treasury. This figure may be used by shareholders as the denominator to determine if they are required to notify their interests in, or a change to their interests in, the Group under the Disclosure Guidance and Transparency Rules.
-Ends-
Contact details
Clinigen Group plc | Tel: +44 (0) 1283 495010 |
Shaun Chilton, Group Chief Executive Officer | |
Martin Abell, Group Chief Financial Officer | |
Numis Securities Limited | Tel: +44 (0) 20 7260 1000 |
Michael Meade / Freddie Barnfield (Nominated Adviser) James Black / Tom Ballard (Corporate Broking) | |
RBC Capital Markets - Joint Broker | Tel: +44 (0) 20 7653 4000 |
Marcus Jackson / Elliot Thomas / Jack Wood | |
Instinctif Partners | Tel: +44 (0) 20 7457 2020 |
Melanie Toyne-Sewell / Alex Shaw | Email: [email protected] |
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.
For more information, please visit www.clinigengroup.com
Related Shares:
CLIN.L